---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010098"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:27:11.925010+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Indaptus Q1 2025: cash burn $5.0M; $3.9M cash; needs capital beyond Q2 2025; Decoy20 combo trial started

## Summary
- Cash and equivalents $3.9M at March 31, 2025, down from $5.8M at Dec 31, 2024; Company needs additional capital beyond Q2 2025.
- Net loss per share $0.32 in Q1 2025 vs $0.45 in Q1 2024; R&D expenses $2.8M (up from $1.6M) due to Phase 1 trial costs.
- Initiated Phase 1b/2 combination arm of Decoy20 with BeOne's PD-1 inhibitor Tislelizumab; weekly dosing arm concluded after 32 patients.
- Patents granted in China, Japan, Israel for Decoy platform; cost-reduction plan implemented to focus on combination study.

## SEC filing metadata
- accession: 0001641172-25-010098
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000164117225010098/0001641172-25-010098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000164117225010098/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010098
- JSON: https://secwatch.observer/filing/0001641172-25-010098.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.